Expand Your Continuum of Care Percutaneous Neurostimulation for Pain

Transcription

1 Expand Your Continuum of Care Percutaneous Neurostimulation for Pain

2 How BiowavePENS Works BiowavePENS delivers therapeutic electrical signals through a patented percutaneous electrode array to block pain signals at the surface of the nerve. BiowavePENS is superior to TENS TENS Transcutaneous Electrical Nerve Stimulation Transmits stimulation across the surface of skin which may act as a distraction to pain (Gate Control Theory) Percutaneous Electrode Array TENS Electrodes Signal Transmission Across Skin Surface Single-Use, Sterile 1014 needles 0.74mm in length Feels like Velcro Location of Pain on Nociceptive Pain Fibers Cross Section of Body Skin BiowavePENS Percutaneous Electrical Nerve Stimulation Transmits stimulation beneath the surface of skin directly to nociceptive fibers blocking the transmission of pain signals to the brain (Frequency Conduction Block Theory) Percutaneous Electrode Arrays Location of Pain on Nociceptive Pain Fibers Cross Section of Body Skin Biowave Active Electrical Field Features BiowavePENS TENS Provides Long Lasting Pain Relief (Up to 72 Hours) Post Treatment 2 Proven to Reduce Opioid Use 1,2 Treatment Provides a Deep, Smooth, Comfortable Sensation 1,2 Easy to Use - No Programming How Does it Work? BiowavePENS is a frequency conduction pain block. The system is comprised of a neurostimulator that delivers high frequency electrical signals through a patented percutaneous electrode array which provides a direct conductive pathway through skin into deep tissue. The high frequency signals travel to the surface of nerves encompassing the pain site. Polarized structures including nociceptive pain fibers cause the high frequency signals to multiply together resulting in the formation of a therapeutic, low frequency active electrical field in a 3.5 diameter hemisphere beneath each percutaneous electrode. The low frequency electrical field hyperpolarizes the C-fibers inhibiting action potential propagation, blocking the transmission of pain signals to the brain. In addition, the low frequency electrical field induces hypoesthesia in the region of the pain site. BiowavePENS is indicated to treat any type of chronic, acute or postoperative pain.

3 Expand Your Co Chronic Back Pain: Cervical, Thoracic or Lumbar TIER 1 Pain Therapies Cognitive & Behavioral Modifications NSAIDs and other OTC Pain Medications TENS Biofeedback Physical Therapy TIER 2 Pain Therapies Systemic Opioids Corticosteroid Injections Nerve Blocks Radio Frequency Ablation TIER 3 Pain Therapies Surgery Implanted Drug Pump Spinal Cord Stimulation (SCS) Following a positive treatment response patients have a choice of subsequent therapies to manage their chronic pain SCS OR Biowave HOME 93%* of patients stop the continuum after Tier 2 therapy 93% are candidates for biowavepens Clinically Proven High Rate of Success Physicians report that more than 75% of patients respond to BiowavePENS treatments 1,2 Substantial Reduction in Pain Scores Patients that respond, report a 50-75% reduction in their VAS pain scores after one thirty minute treatment 1,2,3,4,5,6 Instant & Long Lasting Pain Relief Pain relief is instant as the patient increases the intensity and lasts up to 72 hours post treatment 1,2,3,4,5,6 Reduced Opioid Use BiowavePENS treatments have been proven to lead to a 50% reduction in patient controlled Opioid use 1,2 75% of patients respond positively to BiowavePENS neurostimulation

4 ntinuum of Care Easy to Administer Ease of Use Percutaneous Electrodes can be inserted under the supervision of a Physician by a Physician Assistant, Nurse or Medical Assistant No Programming Patient controls intensity at the touch of a button Shorter Therapy Time Unattended 30-minute treatment Excellent Reimbursement Patients are scheduled for a series of 6 BiowavePENS treatments, typically twice per week over 3 weeks. BiowavePENS treatments are covered by most third party insurance companies and workers compensation. Let Biowave s pre-authorization team secure approval to treat your patients. Pre-authorization with Biowave is painless and free of charge. Covered Payors Workers Compensation Private Insurance and Personal Injury Policies Medicare

5 Getting Started Is As Easy As Proof of Reimbursement Let our reimbursement team get you paid. Biowave will handle the toughest part of the reimbursement process at no cost to you: Pre-Authorization and/or Pre-Bill Review Customized Coding Guide Denial Follow Up Practice Integration Let our integration team get you up and running. Biowave will help you integrate BiowavePENS into your practice s workflow and continuum of care. Patient selection Schedule Management Treatment Optimization Patient Flow Let our marketing team increase your patient flow. Biowave will help you drive incremental revenue for your practice. Point of Service Materials Marketing Programs to Existing Patients Marketing Programs to drive New Patients

6 Biowave Clinical Studies 1. Randomized controlled PENS study on the treatment of post-operative pain from TKA surgery - Hospital for Special Surgery, New York City. Podium Presentation at Eastern Orthopedic Association Annual Meeting, Oct Poster Presentation at AAOS Annual Meeting, February Randomized blinded controlled PENS study treating pain in grade 3 and 4 osteoarthritis of the knee - Rush University Medical Center, Chicago, IL. Published in ORTHOPEDICS June Chronic low back pain dosage study (Phase 1 + 2) - Weill Cornell Medical College, New York City. Abstract - Anesthesia & Analgesia, March Randomized double blinded controlled crossover study comparing Biowave vs. TENS for the treatment of chronic low back pain (phase 3). Weill Cornell Medical College, New York City, September Acute sports injury study on New York Giants professional football players. 600 treatments on 110 players. White paper, June December Controlled clinical study treating extremities to reduce pain and increase range of motion. Coren Clinic, August 2005 References *1. St. Jude Medical Memo on file. SJM-WIT Huang, K. T., Martin, J., Marky. A., Chagoya, G., Hatef, J., Mazzard, M. A.,...Lad, S.P. (2015). A national survey of spinal cord stimulation trial-to-permanent conversion rates. Neuromodulation, 18(2), ; discussion Biowave Corporation 16 Knight Street Norwalk, CT biowave.com BIOWAVE ( )